Medication-Induced Ototoxicity with Furosemide as Primary Culprit
This patient's bilateral tinnitus and vestibular symptoms (unsteadiness with near falls) are most likely caused by furosemide ototoxicity, which should be immediately evaluated and the medication reconsidered. 1
Primary Concern: Loop Diuretic Ototoxicity
The FDA label for furosemide explicitly warns that "cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported" 1. The ototoxicity risk is heightened in this patient due to:
- Chronic use in the setting of cardiovascular disease (she's on carvedilol and candesartan)
- Potential renal impairment (common with heart failure requiring furosemide)
- Concomitant hydroxychloroquine use (though less commonly ototoxic)
The slow onset of bilateral symptoms is consistent with chronic loop diuretic exposure rather than acute sudden sensorineural hearing loss (SSNHL), which typically presents more abruptly 2.
Secondary Consideration: GLP-1 Receptor Agonist Effects
Ozempic (semaglutide) has recently been associated with otologic adverse events, particularly Eustachian tube dysfunction (ETD) and patulous ETD from rapid weight loss 3. The FDA adverse event database shows:
- 958 otologic adverse events (0.99% of total)
- Semaglutide had 1.17% proportion of potential ETD-related events
- Symptoms include ear fullness and autophony 3
However, Ozempic-related ETD typically presents with aural fullness and autophony rather than isolated tinnitus and vestibular symptoms.
Immediate Diagnostic Workup Required
Obtain formal audiometry within 14 days to document sensorineural hearing loss and distinguish from conductive loss 4, 5. The bilateral nature and slow onset raise concern for specific causes per AAO-HNS guidelines 2:
Red Flags to Assess:
- Bilateral sudden hearing loss (rare, suggests systemic/autoimmune cause)
- Fluctuating hearing (suggests Meniere's, autoimmune inner ear disease, or Cogan syndrome—relevant given Sjögren's)
- Focal neurologic symptoms (dysarthria, diplopia, severe headaches, ataxia beyond simple unsteadiness)
- Downbeating or gaze-evoked nystagmus (suggests central pathology) 2
Sjögren's-Specific Considerations:
Sjögren's syndrome itself can cause audiovestibular symptoms through:
- Autoimmune inner ear disease
- CNS vasculitis
- Peripheral neuropathy affecting vestibular function 6
However, the temporal relationship with furosemide use and medication profile makes drug-induced etiology more likely.
Management Algorithm
Step 1: Immediate Actions
- Obtain audiometry (pure tone and speech discrimination) to confirm SNHL
- Check renal function (BUN/Cr) as renal impairment increases furosemide ototoxicity risk 1
- Consult cardiology regarding furosemide alternatives (thiazide diuretics, spironolactone, or dose reduction)
Step 2: If Audiometry Confirms SNHL
- Consider MRI internal auditory canals or auditory brainstem response (ABR) to exclude retrocochlear pathology (vestibular schwannoma), especially given unsteadiness 4
- Autoimmune workup may be warranted given Sjögren's (though she's already diagnosed): ESR, complement levels if considering autoimmune inner ear disease
Step 3: Medication Adjustments
- Discontinue or reduce furosemide if medically feasible (coordinate with cardiology)
- Continue hydroxychloroquine (not typically ototoxic and beneficial for Sjögren's) 7, 8
- Monitor Ozempic for ETD symptoms (ear fullness, autophony) but less likely primary cause 3
- Armodafinil is not associated with ototoxicity
Step 4: Symptomatic Management
If hearing loss/tinnitus persists after medication adjustment:
- Audiologic rehabilitation and counseling 4
- Sound therapy or hearing aids if significant hearing loss documented 9
- Cognitive behavioral therapy if tinnitus becomes bothersome 9
Critical Pitfalls to Avoid
Do not assume this is idiopathic SSNHL requiring corticosteroids without first addressing medication causes—the bilateral, slow-onset pattern is atypical for idiopathic SSNHL 2
Do not continue furosemide without investigation—the FDA explicitly warns about ototoxicity, and reversibility depends on early recognition 1
Do not overlook vestibular symptoms—unsteadiness with near falls suggests vestibulotoxicity (not just cochleotoxicity), which is consistent with aminoglycoside or loop diuretic toxicity 10
Do not delay audiometry—objective documentation is essential for diagnosis and monitoring 4, 5
The combination of bilateral tinnitus and vestibular dysfunction in a patient on chronic furosemide strongly suggests loop diuretic ototoxicity until proven otherwise. Immediate audiometric evaluation and medication review with cardiology consultation are essential to prevent irreversible damage.